Gerresheimer (GXI) AI Stock Analysis

• Market Cap: €1.50B
• Dividend Yield: 0.09%
• Average Volume (3M): 178.25K
• Price to Earnings (P/E): 23.6
• Beta (1Y): 1.24
• Revenue Growth: 9.32%
• EPS Growth: -45.05%
• Country: DE
• Employees: 13,632
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.90
• Shares Outstanding: 34,540,000
• 10 Day Avg. Volume: 189,460
• 30 Day Avg. Volume: 178,247
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €70.18
• Price Target Upside: 62.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9

• Rating: 63 Neutral
• Price Target: €46.00 ▲(6.24% Upside)

Gerresheimer's overall stock score reflects strong financial performance with robust revenue growth and a solid balance sheet. However, technical analysis indicates bearish trends, and valuation metrics suggest moderate pricing with a low dividend yield. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Negative Factors

Gerresheimer Business Overview & Revenue Model

Company Description

Gerresheimer AG (GXI) is a leading global partner for the pharmaceutical and healthcare industries, specializing in the development and production of high-quality glass and plastic products. The company operates primarily in two sectors: Pharmaceuticals and Life Sciences. Gerresheimer's core offerings include glass vials, ampoules, prefillable syringes, and various plastic containers, as well as drug delivery systems and packaging solutions. With a strong emphasis on innovation and sustainability, Gerresheimer serves a diverse clientele, including major pharmaceutical companies, biotech firms, and healthcare providers.

How the Company Makes Money

Gerresheimer generates revenue primarily through the sale of its specialized glass and plastic products to the pharmaceutical and healthcare sectors. The company's revenue model includes direct sales and long-term contracts with key clients, which provide consistent income streams. Significant revenue comes from the production of packaging solutions that comply with stringent regulatory standards, catering to the growing demand for safe and effective drug delivery systems. Additionally, Gerresheimer invests in research and development to create innovative products that meet evolving market needs, enhancing its competitive edge. Partnerships with major pharmaceutical companies and collaborations in product development further contribute to its earnings, as they foster long-term relationships and create additional revenue opportunities.

Gerresheimer Financial Statement Overview

Summary

Gerresheimer shows strong revenue growth and a solid balance sheet with minimal debt. However, there are pressures on profitability and cash flow due to increased operating costs and capital expenditures. The company's financial health is robust, but managing cash flow and maintaining profitability margins will be crucial for sustaining long-term growth.

Income Statement

The income statement shows a consistent revenue growth from 2020 to TTM (Trailing-Twelve-Months) 2025, indicating strong market demand and business expansion. Gross profit margin remains stable at around 28-30%, suggesting good operational efficiency. However, net profit margin has slightly decreased in TTM due to reduced net income, highlighting potential cost pressures. EBIT and EBITDA margins are healthy, but EBIT has declined in TTM, which could reflect increased operating expenses or other operational challenges. Overall, the company demonstrates strong revenue growth with stable, yet slightly pressured, profitability margins.

Balance Sheet

The balance sheet reflects a strong equity position with a debt-to-equity ratio of approximately 0 in TTM, indicating no financial leverage risk. The equity ratio stands at about 31%, reflecting a solid capital structure. Return on equity is slightly reduced in TTM due to lower net income, but it remains reasonable. The decrease in total liabilities over time strengthens the company's financial stability. Overall, the balance sheet demonstrates a robust financial position with strong equity backing and minimal debt risk.

Cash Flow

The cash flow statement shows variability in free cash flow, with a negative free cash flow in TTM due to high capital expenditures. Operating cash flow remains positive but has decreased in TTM, indicating potential operational cash generation challenges. The operating cash flow to net income ratio is positive but reducing, suggesting efficiency concerns. The free cash flow to net income ratio is negative in TTM, highlighting cash flow constraints. Overall, while operating cash flow is stable, the high capital expenditures impact free cash flow, posing a challenge for future liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.19B	2.04B	1.99B	1.82B	1.50B	1.42B
Gross Profit	614.10M	607.76M	597.31M	546.81M	442.23M	437.61M
EBITDA	421.89M	405.97M	403.89M	340.20M	293.09M	301.41M
Net Income	63.26M	109.72M	116.13M	96.12M	83.79M	88.56M
Balance Sheet
Total Assets	4.76B	3.81B	3.43B	3.35B	2.88B	2.62B
Cash, Cash Equivalents and Short-Term Investments	203.46M	213.06M	122.34M	124.83M	133.78M	100.72M
Total Debt	0.00	1.28B	1.04B	1.22B	1.13B	1.05B
Total Liabilities	3.29B	2.27B	1.96B	2.08B	1.88B	1.72B
Stockholders Equity	1.44B	1.51B	1.45B	1.24B	981.32M	883.83M
Cash Flow
Free Cash Flow	-115.27M	-129.51M	-33.70M	-16.13M	8.45M	49.12M
Operating Cash Flow	239.33M	240.33M	294.34M	221.94M	212.08M	222.19M
Investing Cash Flow	-682.28M	-345.59M	-307.43M	-256.18M	-197.04M	-157.03M
Financing Cash Flow	524.55M	168.27M	40.35M	44.24M	8.03M	-52.15M

Gerresheimer Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GXI, the sentiment is Positive. The current price of 43.3 is above the 20-day moving average (MA) of 43.21, below the 50-day MA of 45.07, and below the 200-day MA of 59.88, indicating a neutral trend. The MACD of -0.66 indicates Negative momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 72.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:GXI.

Gerresheimer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRT	65 Neutral	12.55B	107.71	5.03%	0.45%	3.80%	33.31%
GXI	63 Neutral	€1.50B	23.58	4.33%	0.09%	9.32%	-45.05%
JEN	63 Neutral	935.84M	12.08	8.08%	2.32%	-2.59%	-3.21%
PFV	62 Neutral	1.53B	48.46	6.73%	4.72%	0.00%	0.00%
AFX	60 Neutral	3.94B	24.34	8.75%	1.36%	5.21%	-39.36%
SRT3	59 Neutral	12.55B	130.79	5.03%	0.37%	3.80%	33.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%